Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced  NSCLC : IFCT-GFPC 0502 Phase III Study

 

[pdf]Perol JCO 2012_30-28_3516[/pdf]